The present invention relates to new kinase inhibitors of Formula (I), wherein X is oxygen, &mdash；NH&mdash；, or a direct bond； Y is &mdash；NH&mdash； or a direct bond； n is an integer from 0 to 4； m is an integer from 0 to 4； Cy represents a bivalent radical consisting of a satured (poly)cycle, including fused, bi-, spiro or bridged carbocycles and heterocycles； in particular selected from the group consisting of: Formula (II), Ar is selected from the group comprising: Formula (III), R2 is hydrogen or methyl； R8 is hydrogen, methyl, halogen, or alkynyl； R1 is an aryl or heteroaryl more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.本発明は、新たなキナーゼ阻害剤、より具体的にはＲＯＣＫ阻害剤、かかる阻害剤を含む組成物、特に医薬品、並びに疾患の治療及び予防法におけるかかる阻害剤の使用に関する。特に、本発明は、新たなＲＯＣＫ阻害剤、かかる阻害剤を含む組成物、特に医薬品、並びに疾患の治療及び予防法におけるかかる阻害剤の使用に関する。加えて、本発明は、治療方法、並びに性機能障害、炎症性疾患、眼疾患、及び呼吸器疾患を含む多くの治療指標への適用のための薬剤の製造における上記化合物の使用に関する。【選択図】図１
